Talk to a Viviscal Hair Care Advisor: AU 1800 222 099 - NZ 0800 380 218
The Clinical Trials Process
RESEARCHER

40 females

72 females

15 females

Glynis Ablon, M.D., FAAD, Ablon Skin Institute Research Center, University of California, Los Angeles, California, U.S.A.; and Steven Dayan, M.D., FACS, DeNova Research, Chicago, Illinois, U.S.A.
Thomas J. Stephens & Associates, Inc., Dallas Research Center, Carrollton, Texas, U.S.A.
Glynis Ablon, M.D., FAAD, Ablon Skin Institute Research Center, University of California, Los Angeles, California, U.S.A.
RESULTS

(In progress) 6-month, multi-center, randomized, double-blind, placebo-controlled clinical trial

Hypothesis: ingestion of oral Viviscal supplement will strengthen and promote terminal hairs in female subjects, ages 21-75, who have self-perceived thinning hair

Estimated publication date: summer 2014

6-month double-blind, placebo-controlled clinical trial demonstrated statistically significant results:

  • 18.3% reduction in hair shedding vs. placebo
  • 7.4% increase in hair thickness vs. placebo

Abstract presented: 7th World Congress for Hair Research (2013; Edinburgh, Scotland)

6-month double-blind, placebo-controlled clinical trial demonstrated statistically significant results:

  • 125% increase in terminal hairs vs. placebo group
  • 
  • Significant, self-perceived improvements in overall  hair volume, thickness and scalp coverage
  • 
  • Published: The Journal of Clinical and Aesthetic Dermatology (Nov. 2012)
 

  1. Thomas J. Stephens & Associates, Inc.
  2. Glynis Ablon, M.D., F.A.A.D., Ablon Skin Institute Reasearch Center, University of California, Los Angeles
  3. Brook Jackson, M.D., Skin Wellness Center of Chicago
  4. Thomas J. Stephens & Associates, Inc.
  5. José Marcos Pereira, M.D., Brazil